Follow us on Twitter
twitter icon@FreshPatents


Immunogenic patents

      

This page is updated frequently with new Immunogenic-related patent applications.




 Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof patent thumbnailAntibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating globo-h-positive cancer..
Mackay Medical Foundation The Presbyterian Church


 Cellular vaccine and  inducing an immune response in a subject patent thumbnailCellular vaccine and inducing an immune response in a subject
The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd.


 Influenza virus vectors and uses therefor patent thumbnailInfluenza virus vectors and uses therefor
Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.


 Immunotherapeutic compositions for the treatment of alzheimer's disease patent thumbnailImmunotherapeutic compositions for the treatment of alzheimer's disease
A safe and effective vaccine to prevent, slow, halt or reverse progression of alzheimer's disease in human patients is disclosed. The vaccine includes aβ1-42 or an beta amyloid self epitope (e.g.

 Method for decreasing immunogenicity of protein and peptide patent thumbnailMethod for decreasing immunogenicity of protein and peptide
The present invention relates to a method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof by site-specifically binding a carrier to a protein or peptide, and to the use thereof. The conjugate of the physiologically active protein or peptide of the present invention can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide.
Hanmi Pharm. Co., Ltd.


 Methods of immunizing a subject and compositions related thereto patent thumbnailMethods of immunizing a subject and compositions related thereto
This disclosure relates to methods of immunization comprising administering an effective amount of an immunogenic composition comprising an antigen or vaccine and an adjuvant disclosed herein to a subject in need thereof. In certain embodiments, the adjuvant is 1,8-dihydroxy-9,10-dihydroanthracen-9-one or derivative thereof.
Emory University


 Combination vaccines with serogroup b meningococcus and d/t/p patent thumbnailCombination vaccines with serogroup b meningococcus and d/t/p
Serogroup b meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“dtp”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type dtp ratios.
Glaxosmithkline Biologicals Sa


 Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus patent thumbnailProteins and nucleic acids useful in vaccines targeting staphylococcus aureus
Disclosed are novel immunogenic proteins derived from staphylococcus aureus, as well as methods for their use in conferring protective immunity against s. Aureus infections.
Evaxion Biotech Aps


 Compositions and methods comprising klk3 or folh1 antigen patent thumbnailCompositions and methods comprising klk3 or folh1 antigen
The present invention provides klk3 peptides, folh1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.. .
Advaxis, Inc.


 Pcsk9 vaccine patent thumbnailPcsk9 vaccine
The present invention relates to the provision of novel immunogens comprising an antigenic pcsk9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of pcsk9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine..
Pfizer Vaccines Llc


Strategies to prevent and/or treat immune responses to soluble allofactors

The present invention relates to the use of immunogenic peptides comprising a t-cell epitope derived from a soluble allofactor and a redox motif such as c-(x)2-[cst] or [cst]-(x)2-c in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore.. .
Life Sciences Research Partners Vzw

Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of human papillomavirus (hpv) infections and related disorders, including cervical cancer and persistent infections associated with hpv. Related compositions (e.g.
Stc.unm

Replication-competent vsv-hiv env vaccines

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative

Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of respiratory syncytial virus (rsv) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g.
Stc.unm

Malarial antigens derived from subtilisin-like protease 2 and vaccines and methods of use

The present invention provides immunogenic compositions comprising one or more subtilisin-like protease 2 antigens, functional fragments or homologs thereof, from various plasmodium species, methods, vectors comprising the antigens, and methods of use for the treatment of malaria and related disease.. .
The Johns Hopkins University

Prevention and treatment of sub-clinical pcvd

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (pcv2) antigen for the prevention and treatment of sub-clinical pcv2 infection in animals, preferably in pigs.. .
Boehringer Ingelheim Vetmedica, Inc.

Immunogenic compositions and expression systems

immunogenic compositions and vaccines against plasmodial infection comprising an rh polypeptide or a fragment or variant thereof are disclosed. Also disclosed are rh5 polypeptides or fragments or variants thereof capable of binding cd147 and conferring protection against infection and/or disease caused by multiple plasmodial strains or plasmodial species, inhibitors of the interaction between rh5 and cd147 and methods for producing polypeptides in a mammalian expression system..
Genome Research Limited

Novel methods for freeze-drying and rehydrating biologics

The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells.
L'institut National Superieur Des Sciences Agronom Iques De L'alimentation Et De L'environment

Recombinant poxvirus vector comprising tetanus toxin fragment c

The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment c for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment c (ttc) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject..
Bavarian Nordic A/s

Expression of chimeric ksac protein and producing soluble proteins by high pressure

The present invention encompasses vaccines or compositions comprising the chimeric ksac protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic ksac protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes..
Merial Inc.

Combinatorial platform for the display of surface adjuvants and antigens

Engineered bacteria are provided that produce modified lipid a and a polypeptide or polysaccharide antigens. In some aspects, immunogenic compositions are provided comprising a modified a lipid a and a polypeptide or polysaccharide antigen..
Board Of Regents, The University Of Texas System

Anti-b7-h3 antibodies and diagnostic uses thereof

Provided herein are b7-h3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of b7-h3.
Spring Bioscience Corporation

Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function

Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital

Mrka polypeptides, antibodies, and uses thereof

The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject..
Medimmune, Llc

Novel immunogenic composition

Recombinant chimeric viruses based on ndv lasota strain and containing either iltv gb or gd are produced. Administration of the chimeric viruses to chickens induces an immune response in the animal against both ndv and iltv.
The United States Of America, As Represented By The Secretary Of Agriculture

Multivalent vlp conjugates

The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc

Salmonella choleraesuis-salmonella typhimurium vaccines

The present invention relates methods of reducing fecal shedding of animals infected with salmonella by use of a vaccine or immunogenic composition of salmonella choleraesuis-typhimurium.. .
Boehringer Ingelheim Vetmedica, Inc.

Ehrlichial invasin for immuniztion, diagnosis, and cell delivery

Disclosed are vaccines containing one or more immunogenic polypeptides derived from an etpe protein from an ehrlichia sp. Or nucleic acid encoding these polypeptides.
Ohio State Innovation Foundation

Immunogenic liposomal formulation

A liposomal composition comprising a liposome and an aminoalkansulfonic buffer is described and claimed.. .
Glaxosmithkline Biologicals, Sa

Vaccine compositions comprising a saponin adjuvant

The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of quillaja saponaria molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 μg. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 μg of a lipopolysaccharide and between 1 and 30 μg of an immunologically active saponin fraction presented in the form of a liposome..
Glaxosmithkline Biologicals S.a.

Immunogenic composition

The present application discloses an immunogenic composition comprising at least 2 different n. Meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of mena, menc, meny and menw which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of mena, menc, meny and menw which is/are directly conjugated to a carrier protein(s)..
Glaxosmithkline Biologicals S.a.

Immunogenic peptides for inhibition and treatment of herpes simplex virus infection and conditions

Certain embodiments of the present invention provide immunogenic compositions that comprise one or more peptides having an amino acid sequence selected from the group consisting of nllttpkft and rmlgdvmav and methods for administering such compositions to a mammal and thereby inducing in the mammal a cd8+ t cell-dependent protective immunity against an hsv-1 infection, an hsv-2 infection, an hsv-1 condition, an hsv-2 condition, or combinations thereof.. .
The Regents Of The University Of California

Compositions, methods and uses for thermally stable human papillomavirus formulations

Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (hpv) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing hpv formulations in the presence or absence of adjuvants.
The Regents Of The University Of Colorado, A Body Corporate

Novel compositions and methods

The present invention is directed to a polypeptide which comprises: (i) an rv2386c protein sequence; (ii) a variant of an rv2386c protein sequence; of (iii) an immunogenic fragment of an rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis..
Glaxosmithkline Biologicals S.a.

Compounds and compositions as toll-like receptor 7 agonists

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with toll-like receptor 7 activity.. .
Novartis Ag

Immunogenic composition for use in therapy

This application relates to immunogenic compositions comprising a staphylococcus aureus type 5 capsular saccharide conjugated to a carrier protein to form a s. Aureus type 5 capsular saccharide conjugate..
Glaxosmithkline Biologicals S.a.

Factor viii b cell epitope variants having reduced immunogenicity

Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
Bloodworks

Plasmodium falciparum antigens

The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against plasmodium falciparum. The inventive antigens were identified by their association with sterile immunity against malaria..
United States Of America As Represented By The Secretary Of The Navy

Epitopes cross-reactive between hsv-1, hsv-2 and vzv and methods for using same

The invention provides epitopes of hsv and vzv that are cross-reactive and are useful for the prevention and treatment of alphaherpesvirus infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against whole virus.
University Of Washington

Treatment of prdc in pigs

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (pcv2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (prdc) in animals, preferably in pigs.. .
Boehringer Ingelheim Vetmedica, Inc.

West nile virus vaccine

The invention provides for immunogenic compositions against west nile virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.
Boehringer Ingelheim Vetmedica, Inc.

Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (pcv2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a pcv2 infection.
Boehringer Ingelheim Vetmedica, Inc.

Live salmonella vaccine and methods to prevent fowl typhoid

We constructed s. Gallinarum strains deleted for the global regulatory gene fur (fig.
Arizona Board Of Regents On Behalf Of Arizona State University

Indoleamine 2,3-dioxygenase based immunotherapy

The use of ido and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.. .

Compositions comprising angiogenic factors and methods of use thereof

The present invention provides recombinant listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a pest-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.. .
The Trustees Of The University Of Pennsylvania

Pegylated tissue kallikrein, and preparation method therefor and uses thereof

The present invention relates to polyethylene glycol (peg) modified protein drugs, and a pegylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in seq id no.
Gensun Institute Of Biomedicine Co.,ltd.

Endoglin antibodies

The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both.
Tracon Pharmaceuticals, Inc.

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an agent that decreases or inhibits tigit expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.. .
Genentech, Inc.

Compounds and compositions as toll-like receptor 7 agonists

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with toll-like receptor 7 activity.. .
Novartis Ag

Rna containing modified nucleosides and methods of use thereof

This invention provides rna, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of rna, oligoribonucleotide, and polyribonucleotide molecules..
The Trustees Of The University Of Pennsylvania

Novel use of multi-arm polyethylene glycol modifier and application of multi-arm polyethylene glycol modifier in l-asparaginasum modification

Methods for use of a multi-arm polyethylene glycol (peg) modifier in modification of asparaginase. The described multi-arm peg modifier enhances the subunit interaction of a multimeric protein to maintain the multimeric protein in a polymerized form, thereby improving the stability of the multimeric protein, maintaining the bioactivity of the multimeric protein, and reducing the probability of exposure of the antigen binding site after depolymerization of the subunits, so as to reduce the immunogenicity..
Gensun Institute Of Biomedicine Co.,ltd.

Antibody-mediated disruption of quorum sensing in bacteria

The invention provides an immunogenic molecular entity and related vaccines that can be used to inhibit gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a gram-positive bacterial infection. The invention also provides methods of inhibiting gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a gram-positive bacterial infection..

Compositions for antigen-specific induction of tolerance

The invention relates to an immunogenic composition far sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a bifidobacterium and a lactic acid bacterium, and or a combination of a corticosteroid with vitamin d3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable tor sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance..
Stallergenes

Chimeric therapeutics, compositions, and methods for using same

Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule.
Biomed Realty, L.p.

Recombinant turkey herpesvirus vaccines and uses thereof

The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions comprising such recombinant viral vectors and methods for preventing or inhibiting marek's disease in combination with at least a second disease in poultry..
The Texas A&m University System

Chlamydia antigens and uses thereof

The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., t cell-mediated and/or b cell-mediated immune responses).
Genocea Biosciences, Inc.



Immunogenic topics:
  • Immunogenic
  • Polypeptide
  • Recombinant
  • Amino Acid
  • Amino Acid Sequence
  • Immune Response
  • Mycobacterium
  • Vaccination
  • Monoclonal
  • Monoclonal Antibody
  • Antibodies
  • Cytotoxic T Lymphocyte
  • Lymphocyte
  • Amino Acids
  • Hla Antigen


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunogenic for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunogenic with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4243

    file did exist - 2629

    2 - 1 - 56